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Abstract
Alemtuzumab is a monoclonal antibody that targets cell surface CD52 and is effective in depleting lymphocytes by cytolytic
effects in vivo. Although the cytolytic effects of alemtuzumab are dependent on the density of CD52 antigen on cells, there
is scant information regarding the expression levels of CD52 on different cell types. In this study, CD52 expression was
assessed on phenotypically distinct subsets of lymphoid and myeloid cells in peripheral blood mononuclear cells (PBMCs)
from normal donors. Results demonstrate that subsets of PBMCs express differing levels of CD52. Quantitative analysis
showed that memory B cells and myeloid dendritic cells (mDCs) display the highest number while natural killer (NK) cells,
plasmacytoid dendritic cells (pDCs) and basophils have the lowest number of CD52 molecules per cell amongst lymphoid
and myeloid cell populations respectively. Results of complement dependent cytolysis (CDC) studies indicated that
alemtuzumab mediated profound cytolytic effects on B and T cells with minimal effect on NK cells, basophils and pDCs,
correlating with the density of CD52 on these cells. Interestingly, despite high CD52 levels, mDCs and monocytes were less
susceptible to alemtuzumab-mediated CDC indicating that antigen density alone does not define susceptibility. Additional
studies indicated that higher expression levels of complement inhibitory proteins (CIPs) on these cells partially contributes
to their resistance to alemtuzumab mediated CDC. These results indicate that alemtuzumab is most effective in depleting
cells of the adaptive immune system while leaving innate immune cells relatively intact.
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Introduction
CD52 is a cell surface glycoprotein consisting of a short 12 aa
peptide with a C terminal GPI anchor. It is present on human
chromosome1 [1] and is known to have two alleles that differ in
two bases coding for amino acids at C-terminal side of the GPI
attachment region. The two alleles are thought to code for
identical mature antigens and individuals of different genotypes do
not exhibit phenotypic differences [2]. CD52 is expressed on
lymphocytes, monocytes, eosinophils and in the male reproductive
tract on epithelial cells of the epididymis and seminal vesicle. The
CD52 antigen is secreted into seminal plasma where it is taken up
by mature sperm [2,3].
Alemtuzumab is a humanized monoclonal antibody to human
CD52, genetically engineered by grafting rat complementarity
determining regions (CDRs) into human framework regions fused
to human IgG1 [4]. It binds to the C-terminal part of the peptide
to an epitope that includes part of the GPI anchor [5].
Alemtuzumab has been approved for the treatment of patients
with advanced chronic lymphocytic leukemia (CLL) [6,7,8]. This
antibody has also been utilized in the treatment of a wide range of
diseases including rheumatoid arthritis [9,10,11], non-Hodgkin’s
lymphoma [12,13] and T- cell lymphoma [14,15]. In recent phase
2 (CAMMS223) clinical studies, alemtuzumab showed efficacy in
the treatment of relapsing-remitting multiple sclerosis [16].
Alemtuzumab induces potent cytolysis of CD52 expressing
lymphocytes. Although the predominant mechanism of lysis is
not certain, antibody dependent cellular cytotolysis and comple-
ment dependent cytolysis are presumed to be important
[17,18,19,20]. In addition, caspase-8 dependent and independent
apoptosis have also been identified as other potential mechanisms
of cytolytic action by alemtuzumab on cell lines and CLL cells
[21,22,23].
Although alemtuzumab has potent cytolytic effects on mature
lymphocytes, hematopoietic stem cells (HSCs) and some myeloid
derived cells were found to be less sensitive to alemtuzumab
mediated depletion [24,25,26]. This difference in responsiveness to
cytolytic effects of alemtuzumab has been attributed to the
relatively lower levels of CD52 expression [24,25,26,27]. These
studies highlight the importance of the levels or number of CD52
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which is critical for cytolytic effects, especially complement
dependent cytolysis. In this regard, there is scant information
regarding the absolute numbers of CD52 antigenic determinants
for alemtuzumab on various subsets of PBMC populations and
available information is limited to total B and T cells
[14,24,27,28]. The cell surface expression and the quantitative
levels of CD52 on various lymphocyte and myeloid cell subsets in
human blood leukocytes are not known and information
pertaining to the correlation between the density of CD52
molecules and cytolytic effects of alemtuzumab on phenotypically
distinct subsets is lacking.
In this study, we sought to investigate the qualitative expression
and quantitative levels of CD52 antigen density on phenotypically
distinct subsets of lymphocyte and myeloid cell populations in
peripheral blood mononuclear cells (PBMCs) from normal human
donors. In addition, we tested the complement mediated cytolytic
effects mediated by alemtuzumab on human PBMC subsets to
investigate the correlation between the amount of cytolysis and the
quantitative levels of CD52. While cytolytic effects correlated with
antigen density on a majority of PBMC subsets, CD52 antigen
density did not correlate with the degree of cytolysis for some
myeloid cell populations and our studies indicated that they
expressed higher levels of complement inhibitory proteins. These
results provide new insights into differential cytolytic effects of
alemtuzumab on immune cells.
Materials and Methods
Donors and Blood Collection
The donors comprised 22 normal individuals from whom fresh
blood was obtained after informed consent by drawing 10 ml of
venous blood into tubes containing potassium EDTA.
Antibodies
The following fluorochrome conjugated antibodies were used
for flow cytometric analysis: anti CD3-FITC, anti CD27-PE or
APC, anti CD46-PE, anti CD55-PE, anti CD59-PE anti CD62L-
PE Cy5, anti CD56-PE Cy7, anti CD16-APC Cy7, anti-CD11c-
PE Cy5, anti-CD123-PE, (BD Biosciences, San Diego, CA), anti
CD3-efluor 650, anti-CD11c- Alexa 700, anti CD123-PE Cy7,
anti-HLA-DR-efluor 605, anti-CD19-efluor-450 (ebiosciences,
San Diego, CA), anti CD54RA-ECD, anti HLA-DR-ECD
(Beckman coulter), anti CD19-Pacific Blue, anti-CD3 pacific blue,
anti CD4-APC Cy5.5 and anti-CD8 pacific orange, anti-CD14
pacific orange, (Invitrogen, CA), anti BDCA2-APC (Miltenyi
Biotec, Auburn, CA), alemtuzumab-FITC (Genzyme Corpora-
tion). Purified anti CD55 - clone BRC 216 (abcam, Cambridge,
MA) and purified anti CD59 - clone BRIC 229 (IBGRL Research
products, Bristol, UK) were used as neutralizing antibodies in
some functional experiments.
Fluorochrome Labelling of Alemtuzumab
A clinical lot of alemtuzumab was buffer exchanged to a
concentration of 10 mg/ml in 0.1 mM NaH2CO3 pH=8.0 using
a 10 K cutoff spin column (Millipore, Billerica, MA). 59Fluorescein
isothiocyanate (Invitrogen, CA) was dissolved at 10 mg/ml in
DMSO and added at a 15 fold molar excess to the antibody. The
reaction was carried out at room temp for 2 hrs protected from
light. Labeled antibody was gel purified using Zebra-spin column
(Thermo Scientific, Rockford, IL) that had been equilibrated with
PBS pH=7.2. Concentration and degree of labeling (moles of
dye/mole of protein) were determined using UV absorbance at
280 nm and 494 nm.
Mononuclear Cell Separation
Blood obtained from normal donors was processed for
separation of mononuclear cells. Human peripheral blood was
diluted 1:1 with sterile phosphate-buffered saline (PBS), layered
over Ficoll-Hypaque (GE life sciences, Uppsala, Sweden) and
centrifuged at 1500 rpm for 30 min at room temperature. The
interphase layer of PBMCs was drawn out and the cells were
washed in PBS containing 5% fetal bovine serum (FACS buffer).
Cells were resuspended in cold FACS buffer and were separated
from debris by passing them through a 40 micron cell strainer.
Flow Cytometry and Cell Sorting
For qualitative analysis of CD52 expression, a lymphocyte
cocktail containing pretitered dilutions of fluorescently-labeled
antibodies against CD3, CD27, CD45RA, CD62L, CD56, CD19,
CD8 or CD4, CD16 and FITC labeled alemtuzumab to identify
individual subsets of lymphoid cells and a myeloid cocktail
containing pretitered dilutions of fluorescently-labeled antibodies
against CD123, HLA-DR, CD11c, CD16, CD14, BDCA-2, CD3
and FITC labeled alemtuzumab to identify myeloid populations
were used to perform multicolor flow cytometric analysis. To
assess expression of complement inhibitory proteins (CIPs) on
lymphoid and myeloid subsets from four of the twenty two normal
donors, a cocktail of antibodies to CD27, CD45-RA, CD123,
CD19, CD14, CD3, CD8, CD56, CD11c, CD16, CD3 and HLA-
DR and PE-conjugated antibodies to either CD46, CD55 or
CD59 CIPs were used in separate experiments. Briefly, each
cocktail of antibodies was mixed together with 1610
6 PBMCs in
the wells of a 96-well U-bottom plate and incubated on ice for
30 min. The cells were subsequently washed in FACS buffer and
fixed in PBS containing 0.5% paraformaldehyde. One hundred
thousand events of the stained cells were acquired on a BD LSR-II
cytometer and the data were analyzed using FlowJo 7.2 version
Software and expressed as median fluorescence intensity (MFI).
Quantitation of cellular CD52 expression in antibody binding
capacity (ABC) units was performed using Quantum Simply
Cellular anti-human IgG beads (Bangs Laboratories, Inc; Fisher,
IN, USA). The beads are uniform cell-sized microspheres with
different calibrated binding capacities of goat anti-human IgG (Fc
specific) coated on their surface. There are four coated populations
of beads with differing antibody binding capacities (ABC) for
human monoclonal antibodies. The beads were labeled with
FITC-conjugated alemtuzumab in the same manner as the cells
labeled with cocktails of antibodies described above and data were
acquired on a BD LSR-II flow cytometer. The median values of
fluorescence intensity (MFI) of the beads were converted to ABC
units using Quick Cal software to construct a standard calibration
curve. Since the PBMCs are labeled and acquired on the same
flow cytometer using similar instrument settings as the beads, the
standard curve provides a means to convert the median
fluorescence intensity values of phenotypically defined subsets
into absolute numbers (ABC units) of CD52 molecules on cells.
For cell sorting, freshly isolated PBMCs were stained with
antibodies to CD3, CD19, CD56, CD14 and CD11c. Three way
sorting was performed on a FACS Aria (Beckton Dickinson,
SanDiego, CA) to separate purified populations consisting of
CD3+T cell, CD56+ NK cells and CD14+ CD11c+ monocytes
after gating out CD19+ B cells in the dump channel. Cytolytic
experiments were performed on purified cell populations as
described in the next section below.
Complement-dependent Cytolysis (CDC) Assay
For the CDC assay, 1610
6 Ficoll-purified PBMCs were
incubated with 10 mg/ml of alemtuzumab or control human
Heterogeneous CD52 Expression on Human PBMCs
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complement (Quidel Corporation, San Diego, CA) was added to
the cells at a final concentration of 10% (v/v) and incubated for
3 hrs at 37uC in a humidified atmosphere containing 5% CO2.
Following CDC, cells were washed with HBSS/4% HSA medium
and incubated in FACS buffer with a combination of fluoro-
chrome labeled antibodies to CD27, CD45-RA, CD123, CD19,
CD14, CD8, CD56, BDCA-2, CD11c, CD16, CD3 and HLA-DR
for 30 min on ice. In some experiments, CDC was performed on
purified populations of T cells, NK cells and monocytes in the
presence or absence of neutralizing antibodies to CD55 and
CD59.The cells were subsequently washed and stained with
Annexin-V in 150 ml of binding buffer for 15 min at room
temperature. 7-AAD (7.5 ml) was added to the cell suspension and
incubated for an additional 10 min after which 25 ml of Count
Bright absolute counting beads (Invitrogen, CA) were added to
each sample. A minimum of 100,000 events were acquired from
each sample on a BD LSR-II flow cytometer and the data were
analyzed using FlowJo 7.2 version Software. The number of cell
events of each PBMC subset among the cells that survived
cytolytic effects was obtained by analyzing equal numbers of cells
from control IgG and alemtuzumab treated samples after
normalizing the number of cell events by concatenation in Flowjo
software. The absolute cell number of each PBMC subset was then
calculated using the formula,
# of cell events 6 assigned bead count of the lot = absolute
number of cells/100 ml of sample volume
# of bead events.
Results
Polychromatic Flow Cytometry (PFC) Reveals Distinct
PBMC Subsets
Multiple subsets of cells representing various stages of differen-
tiation and activation associated with distinct phenotypic and
functional characteristics have been defined in human peripheral
blood leukocytes [29,30,31,32]. To better define the pattern of
expression of CD52 on leukocyte subsets we used PFC to first
define and characterize multiple populations of lymphocytes and
myeloid cells. Analyzing multiple cell surface markers simulta-
neously, we first defined phenotypically distinct cell populations
corresponding to lymphocyte, myeloid and plasmacytoid cell
lineages in PBMCs from 22 normal donors. Figure 1 shows one
representative analysis and the phenotype of each individual
PBMC subset is provided in Table 1. As shown in Figure 1A, we
identified two B cell populations representing naive and memory B
cell subsets (Panel c), four subsets each of CD4 and CD8
populations corresponding to naı ¨ve, central memory, effector
memory and effector T-cells (panels e and f), and two subsets of
NK cells based on differential expression of CD16 and CD56
(Panel g). A similar analysis defining populations of myeloid and
lymphoid derived plasmacytoid dendritic cells is shown in
Figure 1B. Here, we identified two subsets of CD14+ CD11c+
monocytes (Panel c) and two subsets of CD11c+ HLADR+
myeloid DCs based on differential CD16 expression (Panel e). In
addition, CD11c negative cells could be separated into plasma-
cytoid dendritic cells (pDCs) (panel f) and basophils (panel g) based
on the expression of HLA-DR, CD123, and BDCA2.
PBMC Subsets Exhibit Differential Expression of CD52
Qualitative expression of CD52 on phenotypically defined
PBMC subsets as described above was assessed by examining the
intensity of staining which corresponds to the ability of
alemtuzumab to detect CD52 expression. Representative histo-
grams and median fluorescence intensity (MFI) values from one
donor are shown in Figure 2. The results show that there is a
significant differential pattern of CD52 expression among the
PBMC subsets. The data on lymphocytes (Figure 2A) reveal that
while memory B cells exhibit the highest expression followed by
subsets of T cells, NK cells show much lower levels of CD52
expression. In nineteen of twenty two donors, naı ¨ve B cells showed
heterogeneous CD52 expression allowing delineation into CD52hi
naı ¨ve and CD52lo naı ¨ve subsets (Fig 2C and Table S1). Among
the myeloid cells (Figure 2B), the CD16+ monocytes and mDCs
show higher levels of CD52 expression than their corresponding
CD16 low subsets. Basophils exhibit the lowest CD52 expression.
Similar to naı ¨ve B cells, there was heterogeneous CD52 expression
levels on plasmacytoid dendritic cells (pDCs) that allowed
separation of these cells into a CD52hi and CD52lo subsets in
all the donors examined (Fig 2C and Table S1).
Quantitative Analysis of CD52 Levels on PBMC Subsets
We next ascertained the absolute numbers of CD52 molecules
on each of the individual subsets in PBMCs from all donors in
order to evaluate to what extent the variable CD52 expression
translates quantitatively. Quantitative flow cytometry was per-
formed using Quantum Simply Cellular beads (see materials and
methods) and a calibration curve was generated from the
fluorescence intensity values obtained with a saturating concen-
tration of alemtuzumab (Figure 3). PFC was performed on PBMCs
and the number of CD52 molecules expressed as ABC units for
each of the PBMC subsets were obtained from the standard curve.
Mean CD52 levels are summarized in Figure 4 and Table S1
shows CD52 levels on each individual subset from every donor.
The hierarchy in quantitative levels of CD52 expression on
lymphoid (Figure 4A) and myeloid populations (Figure 4B) mirrors
exactly that observed in qualitative expression in all the donors
studied. Memory B cells have the highest levels of CD52
expression (Avg =634692668919 ABC units) and the CD16lo
CD56 hi NK subset expresses the lowest levels (Avg
=135418643632 ABC units). CD52 antigen density on the
subsets of CD4 T cells was much higher than on the corresponding
subsets of CD8 T cells. The effector CD8 T-cells have lower
average levels of CD52 antigen compared to other T cell subsets in
the majority of donors (Avg =205559651904 ABC units).
Among the myeloid cell populations, CD16+ monocyte (Avg
=4810836137931 ABC units) and CD16+ DC subsets (Avg
=4340116129432 ABC units) express the highest CD52 levels.
CD16 negative monocytes and mDCs show much lower average
levels of CD52 than CD16+ subsets although the average levels
were higher to those expressed by CD8 effector cells. Basophils
(Avg =72308630230 ABC units) show the lowest CD52 expres-
sion levels. This trend of differential CD52 expression pattern was
consistent in all the donors.
These results provide the first comprehensive analysis of
qualitative and quantitative expression levels of CD52 on human
lymphoid and myeloid PBMC subsets. They demonstrate that
CD52 expression among PBMC subsets is highly heterogeneous
but follows the same hierarchical expression pattern across
multiple normal donors examined.
PBMC Subsets Exhibit Differential Susceptibility to
Alemtuzumab Mediated Cytolysis
We next investigated the extent to which the heterogeneous
CD52 levels may confer differences in sensitivity to alemtuzu-
mab mediated cytotolysis. CDC experiments were performed on
PBMCs from four donors using a flow cytometry based assay
which allows for simultaneous assessment of the total number of
Heterogeneous CD52 Expression on Human PBMCs
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lymphoid (A) and myeloid (B) subsets from PBMCs. Mem B (Memory B-cells), CM (Central memory), EM (Effector memory), NK (Natural killer), mDCs
(Myeloid Dendritic cells), pDCs (Plasmacytoid dendritic cells).The phenotype of each PBMC subset is detailed in Table 1.
doi:10.1371/journal.pone.0039416.g001
Table 1. Cell surface phenotypic characteristics of human PBMC subsets.
Surface Phenotype Lymphocyte Subset name
CD32 CD19+ CD272 Naı ¨ve 2 B
CD32 CD19+ CD27+ Memory 2 B
CD192 CD3+ CD4+ CD82CD45RA+ CD27+ CD4 2 Naı ¨ve
CD192 CD3+ CD4+ CD82CD45RA2 CD27+ CD4 2 Central Memory
CD192 CD3+ CD4+ CD82CD45RA2 CD272 CD4 2 Effector Memory
CD192 CD3+ CD4+ CD82CD45RA+ CD272 CD4 2 Effector
CD192 CD3+ CD42 CD8+CD45RA+ CD27+ CD8 2 Naı ¨ve
CD192 CD3+ CD42 CD8+CD45RA2 CD27+ CD8 2 Central Memory
CD192 CD3+ CD42 CD8+CD45RA2 CD272 CD8 2 Effector Memory
CD192 CD3+ CD42 CD8+CD45RA+ CD272 CD8 2 Effector
CD32CD192CD56hi CD16lo CD16lo NK
CD32CD192CD56lo CD16hi CD16hi NK
Surface Phenotype Myeloid subset name
CD32 CD192 HLA2DR+ CD11c+ CD14+ CD16+ CD16+ Monocyte
CD32 CD192 HLA2DR+ CD11c+ CD14+ CD162 CD162 Monocyte
CD32 CD192 HLA2DR+ CD11c+ CD142 CD16+ CD16+ Myeloid dendritic cell
CD32 CD192 HLA2DR+ CD11c+ CD142 CD162 CD162 Myeloid dendritic cell
CD32 CD192 HLA2DR+ CD11c2 CD142 CD123+ BDCA2+ Plasmacytoid dendritic cell
CD32 CD192 HLA2DR2 CD11c2 CD142 CD123+ Basophils
doi:10.1371/journal.pone.0039416.t001
Heterogeneous CD52 Expression on Human PBMCs
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39416dead cells and the absolute number of individual PBMC subsets
among cells that survive cytolytic effects. Figure 5A illustrates
the flow cytometry strategy used. All lymphocytes and myeloid
cells were selected into gate H of Panel 1, based on forward
and side scatter, and the counting beads into a separate gate I.
The cells outside of gate H which were found to be mainly
platelets (data not shown) were excluded from the analysis. As
shown in panel 2, based on 7AAD and Annexin V staining, the
cells were identified as necrotic (7AAD+ Annexin V+), apoptotic
(Annexin V high and 7AAD negative) and live cells (7AAD and
Annexin V negative). The sum of necrotic and apoptotic cells
constituted the total percentage of dead cells. The individual
lymphoid and myeloid subsets within the live cells were
identified using the strategy described in figure 1 and 2 and
the absolute cell number of each subset was calculated as
described in the methods section.
As shown in figure 5B, alemtuzumab mediated signifcant
cytolytic effects as compared to control antibody on PBMCs from
all four donors (44%–68% with alemtuzumab vs 13–19% with
control human IgG1). The absolute number of PBMC subsets that
survived the cytolytic effects of alemtuzumab are presented in
figure 6A–B. The results show that B and T lymphocyte subsets in
alemtuzumab treated samples were significantly reduced com-
pared to human IgG1 treated controls indicating that these cell
populations are effectively depleted with alemtuzumab (figure 6A).
In contrast, this effect of alemtuzumab was not observed on NK
cells and, in fact, there were significantly higher number of NK
cells (p,0.05) in the alemtuzumab treated group in one (914) of
the the four donors. These results indicate that NK cells are
relatively less sensitive than B and T lymphocytes to alemtuzumab
mediated cytolytic effects and that NK cells comprise a majority of
surviving lymphocytes.
In contrast to lymphocytes, the depleting effects of alemtuzu-
mab on myeloid cells was minimal (Figure 6B). Alemtuzumab did
not have significant depleting effects on CD16- monocytes which
Figure 2. Differential expression of CD52 on human PBMC subsets. Representative histograms of CD52 expression levels on each of the
lymphoid (A) and myeloid (B) cell subsets described in figure1 were analyzed using Flowjo software v7.2. The histograms and the corresponding
median fluorescence intensity value of each of the subsets are shown in the panels. A: Hierarchy of CD52 levels on lymphoid cells. Mem B .
CD42CM . CD42EM . CD42Naı ¨ve . CD82Naı ¨ve2.Naı ¨ve2B . CD82CM . CD42Effector . CD16lo Nk . CD16hi NK. B: Hierarchy of CD52
levels on myeloid cells: CD16+ mDC . CD16+ Mono . CD162 Mono . CD162 mDC .pDCs . Basophils. C. Representative plots showing
heterogenous expression of CD52 on Naı ¨ve B cells and pDCs.
doi:10.1371/journal.pone.0039416.g002
Figure 3. Calibration of Simply Quantum cellular microspheres
with alemtuzumab. Uniformly sized microspheres coated with
different numbers (shown above each histogram) of anti-human Fc
molecules defined as antibody binding capacity (ABC) are incubated
with a saturating concentration of FITC-conjugated alemtuzumab
(5 mg/ml). The beads were analyzed by flow cytometry on an LSR-II
instrument and the median fluorescence intensity (MFI) values (shown
next to each histogram) were plotted against the ABC units (shown on
top of each histogram) to generate a standard calibration curve (not
shown). The cells were labeled with alemtuzumab-FITC in the same
manner as the beads and the MFI of CD52 expression on each cell
subset was used to quantify absolute CD52 levels in ABC units or
number of CD52 molecules per cell using the calibration curve.
doi:10.1371/journal.pone.0039416.g003
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depletion (p,0.05) was observed only for CD16+ monocytes from
donor 422 and CD16+ DCs from donor 914. CD16+ subsets of
monocytes and DCs from donors 320 and 425 survived the CDC
effects. CD162 DCs were resistant to alemtuzumab cytolytic
effects and in fact were enriched in numbers in all four donors. In
the remaining myeloid cell populations, interestingly, there were
no significant differences observed between human IgG and
alemtuzumab treated groups indicating that alemtuzumab did not
exert any significant complement mediated depleting effects on
basophils and pDCs. In fact, a significant enrichment of these
subsets was frequently observed after alemtuzumab treatment
(figure 6B). With the combination of antibodies used in the
phenotypic analysis of surviving cells, we could not ascertain the
identity of two subsets of myeloid cells presented in figure 6B as
HLA-DR + and HLA-DR- populations which are significantly
increased (p,0.05) in the alemtuzumab treated group. These have
been presented to account for all the cells in the live gate. It is
likely that these are contaminating granulocytes with HLA-DR+
cells possibly representing eosinophils and HLA-DR- cells being
neutrophils. The apparent increase in the number of cells among
myeloid subsets observed in the alemtuzumab treated group is
most likely due to a significant loss of other PBMC subsets.
Taken together, the results show that while alemtuzumab exerts
complement mediated cytolytic effects on B and T lymphocytes
effectively, NK cells, pDCs and basophils are relatively less
susceptable, demonstrating a cytolytic effect in proportion to the
amount of CD52 on these cells. However, despite expressing
CD52 levels comparable to those of T-lymphocytes, CD16+
subsets of monocytes and mDCs were relatively less susceptible to
alemtuzumab mediated cytolytic effects suggesting that factors
other than antigen density are involved in their resistance to
complement mediated killing.
Monocytes and mDCs Express High Levels of
Complement Inhibitory Proteins
Complement inhibitory proteins (CIPs) are widely expressed
across many cell lineages and protect cells from complement
mediated lysis. There are three major human cell surface CIPs:
CD46 (membrane cofactor protein), CD55 (decay acceleration
factor) and CD59. Since the myeloid cells were relatively resistant
to CDC lysis, we reasoned that differences in the levels of CIP
expression between myeloid and lymphoid cells may be respon-
sible for the lack of sensitivity to CDC. Therefore we examined the
levels of cell surface expression of CIPs on lymphoid and non
lymphoid subsets by flow cytometry. Average relative levels of
median fluorescence imtensity (MFI) on mononuclear cell subsets
from donors on which CDC experiments were performed are
presented in figure 7. All PBMC subsets expressed the three CIPs
although average levels of MFI were significantly different.
Basophils expressed significantly higher levels (p#0.02) of all
three CIPs compared to all lymphocyte subsets. The CD16+ and
CD162 monocytes expressed significantly higher CD46 and
CD55 than lymphocytes (p#0.02). The average CD59 levels on
CD16+ monocytes did not differ significantly from that of
lymphocyte populations, while CD59 levels on CD162 monocyte
were significantly higher compared to only CD8 effector and NK
Figure 4. CD52 antigen density on human PBMC subsets. CD52 expression was determined on subsets of freshly isolated PBMCs from twenty
two normal donors using the strategy described in Fig 1. The number of alemtuzumab binding units to CD52 antigen was determined from the
calibration curve as described in fig 3. The average CD52 antigen density on lymphoid (A) and myeloid (B) subsets of PBMCs is presented with the
error bars representing standard deviation.
doi:10.1371/journal.pone.0039416.g004
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higher and reached statistical significance (p,0.05) compared to
only B cell subsets, effector T cells and NK cells. CD55 expression
on the other hand, was significantly higher (p#0.02) than on all T
cell subsets and NK cells but not B cell subsets. The expression
level of CD59 was higher on CD16+ mDCs but was not
statistically different compared to most of the lymphocyte subsets
except effector subsets of CD4 and CD8 T cells (p#0.03). On
CD162 mDCs, the average CD46 expression was significantly
higher than for effector T and NK cells (p#0.02), whereas CD55
was significantly higher than on NK cells and all T cell subsets
(p#0.02) except naı ¨ve CD8 T cells. CD59 expression on CD162
mDCs was significantly higher compared to naı ¨ve CD8 and
effector T cell subsets of both CD4 and CD8 (p#0.05). Overall,
these results show that monocytes and mDCs express higher levels
of CIPs than lymphocytes and suggest that these proteins may
confer protection to CD16+ monocytes and mDCs from the CDC
effects of alemtuzumab.
Blocking CIPs Partially Reverses the Resistance of
Monocytes to the Cytolytic Effects of Alemtuzumab
Immune cell subsets are present at widely different ratios within
PBMCs. For example, T lymphocytes are present in greater
numbers than NK cells or monocytes which are present in lower
proportions. To ascertain if the higher cytolytic effect of
alemtuzumab on lymphocytes was a direct result of differences
in the levels of CD52 rather than due to a relative abundance
among PBMCs and to validate the role of CIPs on monocytes,
CDC was performed on sorted populations of CD3+ T cells, NK
cells and monocytes in the presence or absence of blocking anti-
CIP antibodies. As shown in figure 8, alemtuzumab depleted
purified T cells to a significant extent with minimal effects on
Figure 5. Complement-dependent cytolytic effets of alemtuzumab on human PBMCs. Cells were incubated with 10 mg/ml of
alemtuzumab or human IgG1 isotype control in the presence of 10% purified human complement for 3 hrs. Alemtuzumab mediated cytotolysis was
assessed by flow cytometry using an LSR-II instrument and a representative dot plot is presented (A). Panel 1 shows the gating strategy. All cells
except platelets and counting beads were included into gate H. Panel 2 shows the dot plot analysis of cells from gate H in panel 1. Live cells are
negative for Annexin-V and 7AAD. Total lysis was calculated by adding total 7AAD (necrotic) and Annexin V positive (apoptotic) cells. (B). The
percentage lysis mediated by alemtuzumab (dark bars) compared to control IgG1(white bars) from each donor is presented. The error bars represent
standard deviation (*p,0.05).
doi:10.1371/journal.pone.0039416.g005
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antibodies. This confirms that the differential cytolytic effects of
alemtuzumab on T lymphocytes and NK cells is primarily due to
differences in the levels of CD52. With purified monocytes,
alemtuzumab had insignificant lytic effect compared to IgG
control in the absence of blocking anti-CIP antibodies. In contrast,
the cytolytic activity of alemtuzumab increased significantly (27 -
36%) in the presence of antibodies to CD55 and CD59 proteins.
However, this cytolytic effect was not to the same extent as
observed for CD3+ T cells suggesting that CIPs contribute only
partially to the resistance of monocytes to alemtuzumab mediated
cytolysis.
Discussion
In the present study, we sought to systematically assess the
qualitative and quantitative levels of CD52 expression on distinct
phenotypic PBMC subsets and evaluate the correlation with
susceptibility to alemtuzumab mediated complement-dependent
cytolysis.
Previous studies have been limited to examination of CD52
expression levels on total B and T lymphocytes. Using radioiso-
topic methods, it was estimated that lymphocytes express 4.5610
5
molecules of CD52 [33]. Ginaldi et. al [14], using a flow
cytometric based approach reported CD52 expression as mole-
cules of equivalent soluble fluorochrome values (MESF) with a
density of 223610
5 MESF values on T cells and lower levels
ranging from 0.522610
5 MESF values on normal B cells. Using a
Figure 6. PBMC subsets that survived the cytolytic effects of alemtuzumab. The absolute cell numbers of individual lymphoid (A) and
myeloid subsets (B) from PBMCs that survived cytolytic effects (live gate of figure 5) from IgG1 treated (white bars) and alemtuzumab treated (filled
bars) of each donor is presented. The error bars represent standard deviation (*p,0.05).
doi:10.1371/journal.pone.0039416.g006
Figure 7. Expression of complement inbitory proteins is higher on myeloid cells than lymphocytes. Expression levels of CD46, CD55 and
CD59 proteins were measured by flow cytometry on individual lymphoid and myeloid cell subsets in PBMCs from donors on whom CDC experiments
were conducted. Average median fluorescence intensity values of each CIP along with standard deviations are shown. * Significantly higher levels
than the lymphocyte subsets (p,0.02)
L Significantly higher levels than B cells, effector T and NK cells (p#0.05) # Significantly higher levels than
effector T and NK cells (p#0.02) @ Significantly higher levels than central memory(CM), effector memory(EM), effector T cells and NK cells (p#0.02)
$ Significantly higher levels than CD4-naı ¨ve, central memory(CM), effector meory(EM), effector CD4 and CD8 T cells and NK cells (p#0.01) &
Significantly higher levels than CD8 effector T and NK cells (p#0.02) ‘ Significantly higher levels than CD8 effector memory and CD4 and CD8
effector T cells (p#0.03) + Significantly higher levels than effector T cells and CD8-naı ¨ve T cell subset (p#0.05).
doi:10.1371/journal.pone.0039416.g007
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levels of 4610
5 molecules on B cells in normal controls. Klabusay
et.al [27] evaluated CD52 antigen expression and showed that B
cells express CD52 at 4610
5 MESF units and reported that it
translated to 1.9610
5 antibody binding capacity units (ABC units).
None of these previous studies assessed CD52 expression levels on
individual lymphocyte subsets and importantly, the absolute CD52
levels on myeloid cell populations were not investigated. The
systematic analysis of PBMCs from normal donors carried out in
the present study demonstrates that the qualitative expression of
CD52 mirrors quantitative levels and that there is significant
differential expression of CD52 among phenotypically distinct
subsets of lymphoid and myeloid cells in all donors tested.
Importantly, the hierarchical pattern of CD52 expression on
PBMC subsets is the same across all donors although the actual
numbers of CD52 molecules per cell on any given subset can vary
from donor to donor (Table S1). The comprehensive quantitative
analysis demonstrates that the number of CD52 binding sites for
alemtuzumab is highly variable. The average CD52 levels
expressed as ABC units on lymphocytes range from 1.3610
5
(SD 64.3610
4) on CD16lo NK cells to 6.3610
5 (SD 66.8610
4)
on memory B cells while on myeloid cells it ranges from 7610
4
(SD 63610
4) on basophils to 4.8610
5 (SD 61.3610
5) on CD16+
monocytes in PBMCs from normal donors (Table S1). The CD52
levels on B and T cells reported in the present study are higher
than those published from radioisotopic and flow cytometry based
studies. Two main reasons could account for these differences: (i)
In previous studies, CD52 levels were either assessed on bulk
lymphocytes [33] or total B or T cell populations [14,27,34],
which would provide an average value of high and low CD52
expressing subsets resulting in lower mean numbers of molecules
per cell. (ii) Differences in the methodologies used; radioisotopic
[33] and MESF based flow cytometry approach [14,34] as well as
a different antibody clone that was used to detect CD52 [27] may
also have played a role. MESF is a quantitative value based on the
intensity of the fluorescence signal from the sample relative to the
signal intensity from a standard fluorochrome coated solution of
microbeads and therefore does not provide the actual number of
molecules on the cell [35]. ABC units, on the other hand, are
derived from the fluorescence intensity of the fluorochrome
conjugated antibody binding to a set of beads that are coated
with specifically calibrated number of anti-immunoglobulin
molecules [35,36]. We chose the latter strategy and used Quantum
Simply Cellular Beads to quantify CD52 antigen density in ABC
units as this method represents a relatively more physiological
interaction between antigen and antibody.
In the process of evaluating cell surface CD52 expression, we
found heterogeneous CD52 expression levels in two PBMC subsets
which allowed for further subdivision of these populations. Within
CD19+ CD27- naive B cells and pDCs, CD52 expression was
variable and each of these subsets could be subdivided into a
CD52 hi and CD52 lo cell population (Figure 2C and Table S1).
While the heterogeneous expression was consistent and was
observed in nineteen of twenty two donors for naı ¨ve B cells, it was
observed in all the subjects studied for pDCs indicating their
frequent presence in PBMCs (Table S1). Whether these subsets are
Figure 8. Alemtuzumab mediates robust cytolysis of purified T cells but not NK cells. Blocking anti CIP antibodies partially reverse the
resistance of monocytes to lysis by alemtuzumab: PBMCs from each of the 4 donors were sorted using a FACS Aria cell sorter into CD3+ T, CD56+ NK
and CD14+ CD11c+ monocytes to .95% purity. Each of these purified populations was subjected to a CDC assay in the presence or absence of
15 mg/ml of anti-CD55 and anti-CD59 antibodies. The percent cytolysis was assessed as described in Fig 5.The hatched bars represent lysis with
alemtuzumab without the blocking anti-CD55 and anti-CD59 antibodies and the shaded bars in the presence of blocking antibodies. The control IgG1
values were subtracted before plotting the data. (Background IgG1 range for T cells =5–10%; NK cells =5215%; and monocytes =15231%).
*p#0.01 (IgG vs Alem alone) **p#0.001 (Alem alone vs Alem + anti-CIP abs).
doi:10.1371/journal.pone.0039416.g008
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tion within each of these cell types with characteristic functional
features is a subject of future studies. These results, however,
demonstrate that CD52 expression represents an additional
marker to delineate hitherto uncharacterized subsets among
peripheral blood cell populations.
Alemtuzumab mediates cytolytic effects through complement-
dependent (CDC) and antibody-dependent cellular cytolytic
(ADCC) mechanisms [37]. CDC depends on the aggregation
and appropriate juxtaposition of antibody molecules bound to the
antigen that results in a conformational change allowing the
constant portion of the antibody to fix complement C1q to initiate
the complement pathway resulting in lysis of the cell expressing the
antigen. This implies that CDC is dependent on the antibody
binding capacity and the density of target antigen on the cell.
Since CD52 antigen density was variable on PBMC subsets, we
investigated whether this variability conferred differences in
susceptibility to the CDC effects of alemtuzumab. We found that
the cytolytic effect of alemtuzumab was very efficient on B and T
lymphocytes that expressed high levels of CD52 (Figure 4B). In
contrast, NK cells, basophils and pDCs which express a
significantly lower CD52 antigen density were not depleted
indicating that cytolytic effects of alemtuzumab were proportional
to the amount of CD52 expressed on the cell surface. Interestingly,
Lowenstein, et.al [38] observed that in normal peripheral blood,
CD4 T cells were more sensitive than CD8 T cells to
alemtuzumab mediated CDC and found CD52 expression levels
on CD4 T cells to be twice that of CD8 T cells. These data were
based on an indirect assay that was used to enumerate dead cells.
In the present study, we also found higher CD52 antigen density
on CD4 T cell subsets than on CD8 T cell subsets, although this
difference was not two fold as reported in the earlier study [38].
Importantly, in contrast to findings of Lowenstein et. al, our data
demonstrate that both CD4 and CD8 T cells are equally sensitive
to CDC by alemtuzumab. Considering the results of our studies on
antigen density and the differential sensitivity to cytolytic effects on
PBMC subsets, it is likely that a threshold of CD52 antigen density
is required for the CDC activity of alemtuzumab. In this regard,
seminal work done by Bindon et. al [33] and others [39,40] in the
late 1980’s has shown the importance of CD52 antigen density on
the lytic activity of anti CD52 antibodies including alemtuzumab
(Campath). Golay et. al [41] have shown that the success of
rituximab in mediating CDC on malignant B cells is highly
dependent on CD20 antigen density. A higher level of CDC
activity was observed with alemtuzumab compared to rituximab
on B-CLL cells and it was found that this difference reflects the
amount of target antigens expressed [42]. Therefore, based on the
correlation between CD52 antigen density and in-vitro cytolytic
effects on PBMC subsets, we speculate that approximately
2.622.8610
5 ABC units of CD52 antigen density (such as on B
& T cells) may be the required lower limit for an efficient
complement-dependent cytolysis by alemtuzumab in the absence
of other factors that may otherwise influence the cytolytic activity.
In contrast to lymphocytes, monocytes and myeloid dendritic
cells were not lysed efficiently with alemtuzumab although these
cells express CD52 levels comparable to B and T lymphocytes
suggesting that antigen density alone is not sufficient to determine
the susceptibility to alemtuzumab mediated lysis. Previous studies
also observed relatively lower sensitivity of monocytes and mature
monocyte derived blood DCs (moDCs) to alemtuzumab mediated
depletion [24,28,43]. It was also shown that with anti-CD52
treatment, malignant and normal lymphocytes are depleted, but
normal and malignant monocytes are resistant despite expressing
large amounts of CD52 antigen [40]. The basis for this resistance,
however, was unknown. One potential mechanism could be the
expression of complement inhibitory proteins (CIPs) whose
function in protecting from autologous complement mediated
lysis has been well documented [44,45]. Our studies indicate that
compared to lymphocytes, monocytes and mDCs express signif-
icantly higher levels of CIPs. Additional experiments conducted in
the presence of neutralizing anti-CD55 and anti-CD59 antibodies
on purified population of monocytes did reveal a significant
increase in their susceptibility to alemtuzumab mediated cytolysis.
However, the average increase in lysis was 31% above the
background which is still lower than the extent to which T cells
were depleted by alemtuzumab treatment. These data indicate
that the higher levels of CIPs on monocytes contribute only
partially to their resistance to alemtuzumab mediated lysis. Thus it
is likely that apart from complement regulatory proteins, there
may be additional cell intrinsic factors that are contributing to the
relative resistance of high CD52 expressing myeloid cells to
cytolysis by alemtuzumab.
In summary, our results demonstrate that human peripheral
blood mononuclear cells exhibit significant variability in quanti-
tative CD52 expression levels and show differential sensitivity to
alemtuzumab mediated complement-dependent cytolysis in vitro.
Our findings show that B and T lymphocytes, which express high
CD52 antigen density, are most susceptible while NK cells, pDCs
and basophils which express low CD52 antigen density are least
susceptible to lysis demonstrating a direct correlation between
antigen density and the complement-dependent cytolytic effects of
alemtuzumab on these cells. However, monocytes and mDCs were
not susceptible to lysis despite the presence of high CD52 antigen
density. While expression of high levels of CIPs is one contributing
factor, there are most likely additional unknown cell intrinsic
factors that seem to confer resistance to these cells. Overall,
alemtuzumab mediated CDC results in efficient lysis of cells from
the adaptive immune system while leaving the components of the
innate immune system relatively intact. These results further our
understanding of the mechanism of action of alemtuzumab and its
potential therapeutic benefit in autoimmune disease indications.
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